Furthermore, Kim et al. [18] demonstrated that the ability of CDDO-Im to inhibit the BRCA1 mutant tumor G2/M cell cycle was associated with DNA damage followed by the activation of the DNA damage checkpoint. Here, BRCA1 is linked to neoplasm.